Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Waiting for reasons to upgrade

Proteomics International Laboratories
3:27pm
March 11, 2024
Following a strong run over the last month, our target price range has now been reached. At the risk of going against clear share price momentum, we continue to wait for further detail on initial launch of the PromarkerD but also note our valuation only assumes commercial success in the US. Significant upside potential remains as the rollout progresses in the US and other jurisdictions, but also view the endometriosis and oesophageal cancer diagnostics will remain key and likely hold significant value with licensing opportunities. We maintain our target price of A$1.38, but our recommendation reduces to a Hold recommendation (from Speculative Buy).

Cost out the focus in a tougher revenue environment

Livehire
3:27pm
March 4, 2024
Given the heavy cost-out initiatives implemented in recent periods (operating costs -28% on pcp), LVH’s 1H24 result showed an improved NPAT loss vs the pcp (-A$4.6m vs -A$7.2m) despite a lower overall revenue performance (1H24 operating revenue of A$3.5m, -11% on pcp). We make several changes to our assumptions over the forecast period (details below). Our price target is reduced to A$0.11 (from A$0.15).

Funding raising provides a path forward

Control Bionics
3:27pm
March 4, 2024
CBL posted its 1H24 result which was an improvement on pcp. Management believe there are sufficient funds to drive the existing business in the core regions of US and Australia as well as move forward some new product development.

Focus on 2H asset sales completing

Cromwell Property Group
3:27pm
March 3, 2024
The key focus remains on reducing gearing and completing the sale of the Polish assets. Management noted that a letter of intent has been signed with binding commitments and if successful expects the sale to occur in 4Q24. Gearing sits at 44.7% and is estimated to fall to c34% post asset sales. No FY24 guidance has been provided, however CMW expects to pay a 0.75c distribution for the March quarter. The payout ratio has fallen vs historical levels (currently around 63%) so we will be looking for further clarity on the group’s longer term payout policy post asset sales and subsequent gearing reduction. We retain a Hold rating with a revised price target of $0.46. The key near term catalyst relates to the sale of the Polish assets.

Adding further scale to Industrial Services

Acrow
3:27pm
March 1, 2024
ACF has added to its Industrial Services capability by acquiring Benchmark Scaffolding in North QLD for $9m (pre earn-outs). The acquisition represents an EV/EBITDA multiple of 3.8x (pre earn-outs), which is largely in line with the MI Scaffold acquisition in November (4x). In our view, the deal is complementary to MI Scaffold and will increase ACF’s scale in Industrial Services in QLD as well as nationally. Management has increased FY24 EBITDA guidance by $1m to between $73-76m as a result of the acquisition. This implies no change to guidance for the existing ACF business. We estimate the deal to be 2% EPS accretive in FY25 (first full year of ownership). Our target price rises to $1.43 (from $1.40) following updates to earnings forecasts and we maintain our Add rating. Trading on 9.3x FY25F PE and 4.7% yield with strong business momentum and leverage to growing civil infrastructure activity over the long term, ACF remains one of our key picks in the small caps space.

Hearing the drum beat loud and clear

Audeara
3:27pm
March 1, 2024
AUA reported its 1H24 results. Key focus around OPEX as timing of restocking and initial EU sales orders remains irregular and hard to predict. Gross margin improvement due to customer mix but likely revert as larger distributors restock. Key news here was maiden sales order from the AUA technology division to drum equipment manufacturer Avedis Zildjian for A$2.1m. Lower margin versus own branded product, but provides scale and volume without the front-ended marketing and sales expense. Deals like this have potential to be a significant part of the business although hard to predict at this stage. Positive share price moves off the back of the technology order, but continue to see higher prices achievable as the business matures. Speculative Buy.

Bumper earnings, focus stays on growth

Karoon Energy
3:27pm
March 1, 2024
KAR delivered a strong December half result, with strong earnings and cash flow. Management flagged a continued focus on its growth. Remaining one of our top sector preferences, we maintain an Add rating.

Continued progress across the bulk of the portfolio

Frontier Digital Ventures
3:27pm
March 1, 2024
FDV’s FY23 NPAT of -A$8.59m (FY22 -A$10.2m) came in better than Morgans expectations (-A$10.5m), whilst statutory revenue (~A$68m, +15% on the pcp) was in-line with Morgans forecasts. While FDV Associate businesses continue to face economic headwinds, this result showed a continued improving earnings trajectory across FDV’s consolidated portfolio, in our view. We lift our FDV FY23F/FY24F EPS by >10% respectively mainly on improved group EBITDA margin assumptions. Our PT is largely unchanged at A$0.79 (previously A$0.77). We continue to be attracted to FDV’s long-term growth profile and the earnings potential of the assembled portfolio. ADD maintained. We lift our FDV FY23F/FY24F EPS by >10% respectively mainly on improved group EBITDA margin assumptions. Our PT is largely unchanged at A$0.79 (previously A$0.77).

Major step forward in cardiac ablation

Imricor Medical Systems
3:27pm
March 1, 2024
Imricor Medical Systems (IMR) develops medical devices for the treatment of irregular heartbeats, which are safer, quicker and more effective than current treatment methods. Current approval (in Europe) for atrial flutter is being expanded into other indications (atrial fibrillation and ventricular tachycardia), which will significantly increase the market potential. According to management and our literature searches, the estimated total addressable market (TAM) is >US$8bn. IMR’s recent capital raising enables it to fund additional clinical studies, reactivate sites in Europe and commercially launch in the Middle East and Australia. We initiate coverage on IMR with a DCF based valuation and target price of A$0.96 and a Speculative Buy recommendation.

1H24 earnings: Hells Bells

The Star Entertainment Group
3:27pm
February 29, 2024
Today, SGR delivered EBITDA of $114m, which fell 8% below our estimates and 16% below consensus. Current trading remains subdued, with January trading consistent with AGM run-rate levels. Despite all this, shares reacted strongly as a result of what believe sounded like positivity towards the progress of its remediation plan and ‘better than feared’ outcomes from the deferral of the result. We decreased our EBITDA assumptions by 14% in FY24, however increase by 12% in FY25, after rolling our model to accommodate the new opening date. Our EPS estimates increase as a result of lower revised D&A and interest expense. We reiterate our Add rating, and our price target of $0.70 remains.

News & Insights

Investment Watch is a flagship product that brings together our analysts' view of economic and investment strategy themes, sector outlooks and best stock ideas for our clients.

Investment Watch is a quarterly publication produced by Morgans that delves into key insights for equity and economic strategy. This latest publication will cover;

  • Asset Allocation – not the time to play defence
  • Economic Strategy – averting a world recession
  • Equity Strategy – attention turns to August
  • Resources & Energy – domestic gas coming to the boil
  • Banks – befuddling
  • Updated Morgans Best Ideas

Morgans clients receive exclusive insights such as access to our latest Investment Watch publication. Download the preview now.

      
View Investment Watch
      

Preview

We think the investment landscape remains favourable. The US economic fundamentals are strong with no significant downside risks to growth in the near-term. European leading indicators suggest a turning point is near and China’s cyclical recovery is still gaining momentum after bottoming earlier in the year.

Meanwhile, the Australian economy continues to defy expectations of a sharper slowdown. In our view, this is not the time to play defence and continue to expect growth assets such as equities and property to do well. This quarter, we look at tactical opportunities in private credit, global equities and across the Australian equity market (resources, agriculture, travel and technology).

Read more
Our best ideas are those that we think offer the highest risk-adjusted returns over a 12-month timeframe supported by a higher-than-average level of confidence. They are our most preferred sector exposures.

As interest rates normalise, earnings quality, market positioning and balance sheet strength will play an important role in distinguishing companies from their peers. We think stocks will continue to diverge in performance at the market and sector level, and investors need to take a more active approach than usual to manage portfolios.

Additions: This month we add Elders.

July best ideas

Elders (ELD)

Small cap | Food/Ag

ELD is one of Australia’s leading agribusinesses. It has an iconic brand, 185 years of history and a national distribution network throughout Australia. With the outlook for FY25 looking more positive and many growth projects in place to drive strong earnings growth over the next few years, ELD is a key pick for us. It is also trading on undemanding multiples and offers an attractive dividend yield.

Technology One (TNE)

Small cap | Technology

TNE is an Enterprise Resource Planning (aka Accounting) company. It’s one of the highest quality companies on the ASX with an impressive ROE, nearly $200m of net cash and a 30-year history of growing its earnings by ~15% and its dividend ~10% per annum. As a result of its impeccable track record TNE trades on high PE. With earnings growth looking likely to accelerate towards 20% pa, we think TNE’s trading multiple is likely to expand from here.

ALS Limited

Small cap | Industrials

ALQ is the dominant global leader in geochemistry testing (>50% market share), which is highly cash generative and has little chance of being competed away. Looking forward, ALQ looks poised to benefit from margin recovery in Life Sciences, as well as a cyclical volume recovery in Commodities (exploration). Timing around the latter is less certain, though our analysis suggests this may not be too far away (3-12 months). All the while, gold and copper prices - the key lead indicators for exploration - are gathering pace.

Clearview Wealth

Small cap | Financial Services

CVW is a challenger brand in the Australian retail life insurance market (market size = ~A$10bn of in-force premiums). CVW sees its key points of differentiation as its: 1) reliable/trusted brand; 2) operational excellence (in product development, underwriting and claims management); and 3) diversified distributing network. CVW's significant multiyear Business Transformation Program has, in our view, shown clear signs of driving improved growth and profitability in recent years. We expect further benefits to flow from this program in the near term, and we see CVW's FY26 key business targets as achievable. With a robust balance sheet, and with our expectations for ~21% EPS CAGR over the next three years, we see CVW's current ~11x FY25F PE multiple as undemanding.

GUD Holdings

Large cap | Consumer Discretionary

GUD is a high-quality business with an entrenched market position in its core operations and deep growth opportunities in new markets. We view GUD’s investment case as compelling, a robust earnings base of predominantly non-discretionary products, structural industry tailwinds supporting organic growth and ongoing accretive M&A optionality. We view the ~12x multiple as undemanding given the resilient earnings and long-duration growth outlook for the business ahead.

Stanmore Resources

Small cap | Metals & Mining

SMR’s assets offer long-life cashflow leverage at solid margins to the resilient outlook for steelmaking coal prices. We’re strong believers that physical coal markets will see future cycles of “super-pricing” well above consensus expectations, supporting further periods of elevated cash flows and shareholder returns. We like SMR’s ability to pay sustainable dividends and its inventory of organic growth options into the medium term, with meaningful synergies, and which look under-recognised by the market. We see SMR as the default ASX-listed producer for pure met coal exposure. We maintain an Add and see compelling value with SMR trading at less than 0.8x P/NPV.


Morgans clients receive full access of the Best Ideas, including our large, mid and small-cap key stock picks.

      
Contact us
      
Read more
There are many reasons to invest in equities. Historically, they have offered higher capital returns than many other asset classes. Furthermore, they provide liquidity and diversification and allow investors to participate in the growth of high performing businesses and sectors.

There are many reasons to invest in equities. Historically, they have offered higher capital returns than many other asset classes. Furthermore, they provide liquidity and diversification and allow investors to participate in the growth of high performing businesses and sectors. Not to be overlooked, however, is their capacity to provide an income stream through regular dividends. In the Month Ahead for July, we highlight a selection of Australian equities that offer superior forecast dividend yields and may be suitable investments for those seeking income.

Happy New Financial Year!

BHP Group (BHP)

BHP Group (ASX: BHP) is the largest diversified mining company in the world. BHP has extensive iron ore, copper, nickel and coal operations, and will soon add potash to its portfolio once its massive Jansen project comes online in late 2026. Besides nickel, which has proven volatile, the rest of BHP’s basket of market exposures share the similar characteristic of typically boasting bumper margins throughout the cycle. Over the last decade BHP has shifted its corporate strategy toward streamlining its business, protecting its balance sheet, slowing its pace of investment and maximising shareholder returns. Despite an impressive shareholder performance over recent years, BHP’s dividend yield has remained above market.

      
BHP coverage report
      

Dalrymple Bay Infrastructure (DBI)

Dalrymple Bay Infrastructure (ASX: DBI). DBI owns a fully contracted coal export terminal in central Qld. It has strong revenue and cost risk mitigants, CPI-linked base revenues boosted by incremental revenues from commissioned sustaining capex projects, very high EBITDA margins, and an investment grade credit profile. Investors comfortable with the coal-related exposure also benefit from the ESG discount imputed into the stock price.

      
DBI coverage report
      

Ventia Services Group (VNT)

Ventia Services Group (ASX: VNT) delivers essential services predominantly to government (c.75% of revenue), with an average contract tenure of c.5-7 years and direct inflation passthrough (95% of revenue) in most contracts. The industry grows at 6-7% pa, with VNT growing 7-10% through industry growth and contract expansion, whilst margins should remain stable. The stock continues to deliver a strong dividend yield, which we expect to continue growing at mid-single digits, whilst trading on an undemanding low double-digit PER.

      
VNT coverage report
      

Eagers Automotive (APE)

Eagers Automotive Limited (ASX: APE) is the leading automotive retail group in Australia and New Zealand, operating for over 100 years and representing a diverse portfolio of OEM (original equipment manufacturer) brands. While current industry dynamics in the auto sector (margin pressure; cost of living impacts) are expected to persist in the near-term, we view the scale operators (such as APE) as best placed to navigate this challenging dynamic. Longer-term, we are positive on APE’s various strategic initiatives and expect it can continue to scale; and sustain a structurally higher return on sales through the cycle.

      
APE research report
      

GQG Partners (GQG)

GQG Partners (ASX: GQG) is global asset management boutique, managing ~US$150bn in funds across four primary equity strategies. We like GQG given its highly effective distribution, scalable strategies, and strong long-term investment performance. We view the earnings tailwind from strong funds under management growth (a combination of investment performance and net fund inflows) will continue and we think GQG will continue to re-rate along with this to a higher earnings multiple in time.

      
GQG research report
      

HomeCo Daily Needs REIT (HDN)

HomeCo Daily Needs REIT (ASX: HDN) has a +$4.5bn real estate portfolio focused on daily needs retail (Large Format Retail; Neighbourhood; and Health Services) across +50 properties with the top five tenants being Woolworths, Coles, JB Hi-Fi, Bunnings and Spotlight. Most of leases are fixed. The portfolio has resilient cashflows, with the majority of tenants being national. Sites are in strategic locations with strong population growth. HDN offers an attractive distribution yield, with a +$600m development pipeline providing further growth.

      
HDN research report
      

IPH Limited (IPH)

IPH Limited (ASX: IPH) is a prominent IP services group with market leading shares in Australia, Singapore and Canada. A defensive business, IPH has strong cash flow generation (with high conversion to EBITDA) and a long-track record of paying dividends to shareholders. We like IPH and consider the return to organic growth (albeit subdued) as a key near-term catalyst for the group. Longer-term, we expect IPH to continue to prosecute its consolidation and network expansion strategy offshore.

      
IPH research report
      

Suncorp (SUN)

Suncorp (ASX: SUN) is well positioned to benefit from continued strong price increases going through the home and motor insurance market in Australia, we expect these price increases to be supportive of SUN’s margins expanding further over the next couple of years. Additionally SUN’s recent divestment of its bank was done at an excellent price and will allow the company to focus completely on its strongest business, general insurance, where it is a market leader.  Finally, post the bank sale, SUN now has >A$4bn of excess capital to return to shareholders, which will occur most likely via the way of a share consolidation and a small special dividend.

      
SUN research report
      

Super Retail Group (SUL)

Super Retail Group (ASX: SUL) is a large discretionary retailer comprising four well-known brands which span several categories, including: Supercheap Auto; rebel Sport; Boating, Camping and Fishing (BCF), and Macpac. We like SUL given its market leading scale (>740 stores), deep data capabilities, strong loyalty base and diversified portfolio of brands. SUL has a very strong net cash balance sheet, and we expect it is positioned for further capital management initiatives in the near-term (i.e. potential special dividends).

      
SUL research report
      

Woodside Energy (WDS)

Woodside Energy (ASX: WDS) is the largest ASX-listed oil and gas producer, and in the top 10 globally. While its share price has come under pressure, Woodside’s fundamentals have benefited from resilient oil/LNG prices, steady group production, progress on delivering its key growth projects, a robust level of profitability, and clear focus on its dividend profile. Woodside’s dividend payout ratio has averaged 80% of earnings for the last +5 years, which is impressive given the last 2 years have been a capex-heavy phase as its progressed construction of the Scarborough, Pluto Train 2, and Sangomar projects. With gearing remaining low and cash flow set to grow post the current investment phase, we see Woodside as likely to remain an attractive yield play.

      
WDS research report
      

Morgans clients receive exclusive insights such as access to the latest stock and sector coverage featured in the Month Ahead. Contact us today to begin your journey with Morgans.

      
Contact Us
      
Read more